
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp is positioned favorably due to its advancing orphan lung pipeline, which is expected to enhance long-term growth and diversification for the company. The management's strategic focus on education and marketing initiatives for Afrezza and Tyvaso DPI may further drive uptake, particularly as Tyvaso DPI gains market share in the pulmonary arterial hypertension (PAH) and pulmonary fibrosis (PF) sectors. Additionally, the potential approval of the Furoscix auto-injector could act as a substantial revenue driver, providing further stability and growth opportunities for MannKind's financial outlook.
Bears say
MannKind Corp's stock faces a negative outlook primarily due to the recent announcement of a competitive product by SQ Innovation, which has contributed to a significant 15.2% decline in share value, contrasting sharply with the broader biotech index performance. Additionally, the potential for successful challenges to the company's intellectual property and the emergence of well-capitalized competitors could adversely affect MannKind's market share and pricing power, particularly in the development of their products MNKD-102 and MNKD-201 for underserved diseases. Furthermore, setbacks from negative trial readouts, regulatory submission issues, or adverse decisions could hinder commercialization efforts and limit market potential, further compounding the company's financial risks.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares